Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Fubotv Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Fubotv Inc trades at $10.15 (market cap $280.89M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 28.6× Fubotv Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| BIO | FUBO | |
|---|---|---|
Market Cap | $8.04B | $280.89M |
Sector | Health | Technology |
52-Week High | $339.75 | $54.72 |
52-Week Low | $241.71 | $8.09 |
Enterprise Value | $7.85B | $451.31M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FUBO trades at $9.83, up 7.08% today, with technical indicators showing neutral signals. The company reported a net loss of $172.25M in 2024, but revenue grew to $1.62B and net income is projected to turn positive in 2025. Recent CEO appointment from Disney has driven positive sentiment, while valuation ratios like P/E of 2.56 and P/S of 0.2 appear attractive relative to historical norms.
Outlook is cautiously optimistic with analyst consensus price target of $16.25 implying 65% upside, supported by streaming growth and new partnerships. Key risks include persistent cash burn and intense competition in the streaming sector. The stock offers value if profitability targets are met, but requires monitoring of subscriber trends and execution on cost controls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
